Lima R. 2004. Information Management and Technology Considerations for ARV Programs in Resource-Constrained Settings. Paper presented at the Institute of Medicine Workshop on Antiretroviral Scale-up in Resource Constrained Settings, Washington, DC. Institute of Medicine Committee on Antiretroviral Drug Use in Resource-Constrained Settings.

Little SJ. 2000. Transmission and prevalence of HIV resistance among treatment-naïve subjects. Antiviral Therapy 5(1)33–40.

Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine 347:385–394.

Loubser S, Sherman G, Chezzi C, Jones S, Cohen S, Puren S, Morris L. 2004. Characterization of nevirapine resistance mutations using RT-PCR and DNA sequencing methods in a mother-infant cohort following single dose nevirapine. Abstract 131. Antiviral Therapy 9:S145.

Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. 2003. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clinical Trials 4(2):115–120.

Médecins sans Frontières. 2003a. Providing HIV Services Including Antiretroviral Therapy at Primary Health Care Clinics in Resource-Poor Settings: The Experience from Khayelitsha. [Online]. Available: http://www.msf.org/source/countries/africa/southafrica/2004/1000/khayelitsha1000.pdf [accessed August 5, 2004].

Médecins sans Frontières. 2003b. Surmounting Challenges: Procurement of Antiretroviral Medicines in Low-and Middle-Income Countries. [Online]. Available: http://www.accessmed-msf.org/documents/procurementreport.pdf [accessed July 1, 2004].

Orrell C, Bangsberg DR, Badri M, Wood R. 2003. Adherence is not a barrier to successful antiretroviral therapy in South Africa AIDS 17(9):1369–1375.

Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 136(3):253.

Pillay C, Bredell H, McIntyre J, Gray G, Morris L. 2002. HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Research and Human Retroviruses 18(8):605–610.

Redfield R. 2004 (January 27). Durability of ARV Therapy: U.S. Experience and its Implications for Resource-Constrained Settings. Paper presented at the Institute of Medicine Workshop on Antiretroviral Scale-up in Resource Constrained Settings, Washington, DC. Institute of Medicine Committee on Antiretroviral Drug Use in Resource-Constrained Settings.

Richman D, Morton S, Wrin T, Hellmann N, Berry S, Shapiro M, Bozzette S. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1–7.

Schechter M. 2004 (January 27). Lessons Learned from the Scale-up of Antiretroviral Treatment in Brazil. Paper presented at the Institute of Medicine Workshop on Antiretroviral Scale-up in Resource Constrained Settings, Washington, DC. Institute of Medicine Committee on Antiretroviral Drug Use in Resource-Constrained Settings.

Sethi A, Celentano D, Gange S, Moore R, Gallant J. 2003. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 37:1112–1118.